Results 111 to 120 of about 11,874 (152)

Profiling the Cerebrospinal Fluid Proteome in Progressive Multiple Sclerosis: Treatment Effects and Associations with IgM Oligoclonal Bands. [PDF]

J Neuroimmune Pharmacol
El Mahdaoui S, Kosa P, Komori M, Veiga González JL, Chow HH, Ratzer R, Madsen CG, Siebner HR, Bielekova B, Villar LM, Romme Christensen J, Sellebjerg F.   +11 more
europepmc   +1 more source

Progressive Multifocal Leukoencephalopathy in AIDS: The Diagnostic Role of PET Imaging. [PDF]

Infect Dis Rep
Donini V, Paggi R, Farese A, Malcontenti C, Tagliaferri E, Caroselli C, Sani S, Matteini M, Bartoloni A, Zammarchi L.   +9 more
europepmc   +1 more source

Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation. [PDF]

Front Pharmacol
Wen H, Dong Y, Wang R.
europepmc   +1 more source

Patient Preference and Time Allocation Associated with Transition from Intravenous to Subcutaneous Administration of Natalizumab (Tysabri) in Patients with Relapsing Remitting MS - A Questionnaire Study. [PDF]

Patient Prefer Adherence
Almroth A, Söderbärg K, Sjöblom I.
europepmc   +1 more source

LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models. [PDF]

Pharmaceutics
Fathallah AM, Ramadan A, Karzoun B, Leahy H, Dave N, Khashan R, Allababidi S, Saidha S, Madani S.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Natalizumab

Neurology, 2009
Since it first came to trial, natalizumab (Tysabri) has kept the multiple sclerosis (MS) world in a constant state of flux. Shortly after its initial launch, the appearance of three cases of progressive multifocal leukoencephalopathy (PML), a devastating infection of the CNS caused by the JC virus, resulted in the drug’s withdrawal from the market ...
Nicoline, Schiess, Peter A, Calabresi
openaire   +3 more sources

Natalizumab update

American Journal of Health-System Pharmacy, 2007
The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of natalizumab are reviewed.Natalizumab, the first commercially available selective adhesion-molecule inhibitor, is approved as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis (MS ...
openaire   +2 more sources